# Jared Tangney

> Jared Tangney is the co-founder, president and chief technology officer of Biolinq, a San Diego medical-device company that grew out of UC San Diego research. A bioengineer and inventor, he helped turn an academic biosensor project into Biolinq Shine, an intradermal glucose sensor that received FDA De Novo classification in September 2025. His career is defined by a thirteen-year translation problem: shrinking electrochemical sensing into a manufacturable silicon array and making its information useful without demanding constant attention from the wearer.

- **Role:** Co-founder, President & CTO at Biolinq
- **Organizations:** Biolinq, Electrozyme, University of California San Diego, Tech Coast Angels
- **Education:** Ph.D., Bioengineering, University of California, San Diego, Certificate, Technology Business Creation, University of California, San Diego, M.S., Bioengineering, University of California, San Diego, B.S., Bioengineering, University of California, San Diego
- **Known for:** Co-founded the university spinout that became Biolinq and remained in technical leadership through its first FDA-classified product., Helped translate UC San Diego biosensor research into a silicon microneedle array platform designed for high-volume manufacturing., Named inventor on multiple Biolinq patent grants and applications covering intradermal biosensors, microneedle arrays and continuous analyte monitoring systems.

## Career timeline

- **2010** — Worked with UC San Diego's entrepreneurship and engineering leadership programs while conducting biosensor research.
- **2012** — Co-founded Electrozyme with Joshua Windmiller from research at UC San Diego.
- **2012** — Won the Rady School of Management Student Venture Open elevator pitch competition.
- **2014** — Completed a Ph.D. in Bioengineering at UC San Diego; Electrozyme won a CONNECT Most Innovative New Product Award.
- **2015** — Electrozyme changed its name to Biolinq.
- **2015-2023** — Served as Biolinq's CEO through its early technology development and financing stages.
- **2023** — Moved into the president and CTO role as Rich Yang became CEO.
- **2025-04** — Biolinq announced a $100 million Series C financing for regulatory and commercial-readiness work.
- **2025-09** — The FDA granted De Novo classification to Biolinq Shine Autonomous Time-in-Range Microsensor.
- **2026-03** — Presented Biolinq's path from university lab to FDA classification at ATTD 2026 in Barcelona.

## Achievements

- Co-founded the university spinout that became Biolinq and remained in technical leadership through its first FDA-classified product.
- Helped translate UC San Diego biosensor research into a silicon microneedle array platform designed for high-volume manufacturing.
- Named inventor on multiple Biolinq patent grants and applications covering intradermal biosensors, microneedle arrays and continuous analyte monitoring systems.
- Won the 2012 Rady School of Management Student Venture Open elevator pitch competition.
- Shared in Electrozyme's 2014 CONNECT Most Innovative New Product Award and IDTechEx product-development recognition.
- Co-authored research on cardiac mechanics and intradermal glucose sensing.

## Latest updates

- **2026-03** — Presented 'The Biolinq Journey: From University Lab to FDA Clearance' at ATTD 2026 in Barcelona.
- **2025-11** — Joined Biolinq CEO Rich Yang on Bloomberg's Vanguards of Health Care podcast to discuss the company's microsensor platform and commercial strategy.
- **2025-10** — Discussed Biolinq's origin, 0.2-millimeter sensor depth and simplified product design in a MedTech Dive interview.
- **2025-09** — Biolinq Shine received FDA De Novo classification; Tangney remained co-founder, president and CTO.
- **2025-04** — Biolinq closed a $100 million Series C financing led by Alpha Wave Ventures.

## Links

- Website: https://www.biolinq.com
- LinkedIn: https://www.linkedin.com/in/jaredtangney

---

Profile page: https://yespress.io/jared-tangney
Published by YesPress — https://yespress.io
Last updated: 2026-09-28